Qiagen cuts full-year 2026 revenue and EPS guidance after preliminary Q1 sales come in below outlook
Qiagen cuts full-year 2026 revenue and EPS guidance after preliminary Q1 sales come in below outlook
- Preliminary Q1 2026 results show EPS in line with outlook despite revenue shortfall versus company expectations.
- Company cites weaker demand for QuantiFERON testing as a key driver of the reduced 2026 guidance.
- Qiagen also reports softer U.S. life sciences activity contributing to lower sales and the guidance reduction.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.